Screening, Classification, and Outcome Prediction Ensemble Using Orbital MRI for Thyroid Eye Disease: The TED SCOPE National Multicenter Registry Study
NCT07716397 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1200
Last updated 2026-07-21
Summary
The goal of this observational study is to prospectively validate the efficacy of an AI multimodal model constructed based on multi - sequence orbital MRI in the diagnosis, activity and severity assessment, and prognosis prediction of thyroid - associated ophthalmopathy (TAO) in real - world clinical scenarios. The main questions it aims to answer are:
Can AI models accurately assess the presence, activity, and severity of Thyroid-Associated Orbitopathy (TAO)? Can AI models predict the prognosis of TAO? Researchers will compare the diagnostic accuracy of the AI model for TAO patients and healthy subjects to evaluate its diagnostic performance.
Participants will undergo a standardized, study - specific multimodal orbital MRI scan (sequences include T1WI, T2WI, STIR, and research sequences such as Magic, IDEAL - IQ, DWI, ASL, CEST). And will systematically acquire ocular ultrasound images from TED patients (active and inactive stages), non-TED ophthalmic disease controls, and healthy volunteers. AI-driven deep learning techniques (convolutional neural networks) will be applied to achieve automatic segmentation of key structures (extraocular muscles, optic nerve, lacrimal gland, and retrobulbar soft tissue). High-throughput radiomic features encompassing morphological parameters and gray-level texture patterns will be extracted. Machine learning algorithms will then be employed to construct objective prediction models for TED screening and activity staging, with MRI findings and CAS scores serving as the reference standards for external validation.
Conditions
- Graves Ophthalmopathy
- Graves Disease
- Thyroid Associated Ophthalmopathies
Interventions
- DIAGNOSTIC_TEST
-
MRI scan,ocular ultrasound
Participants will undergo a standardized, study - specific multimodal orbital MRI scan (sequences include T1WI, T2WI, STIR, and research sequences such as Magic, IDEAL - IQ, DWI, ASL, CEST).
Sponsors & Collaborators
-
Shanghai Changzheng Hospital
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2026-01-01
- Primary Completion
- 2028-12-31
- Completion
- 2028-12-31
Countries
- China
Study Locations
More Related Trials
-
Morphometric Analysis of Orbital Structures in Graves´ Orbitopathy
NCT00665795 ·Status: COMPLETED
-
Teprotumumab N01 Versus Methylprednisolone After Urgent Orbital Decompression for Dysthyroid Optic Neuropathy
NCT07594912 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
The Therapeutic Effect of Dysthyroid Optic Neuropathy
NCT04096612 ·Status: UNKNOWN ·Phase: NA
-
Multi-model Image of Immunosuppressive Agents in TAO
NCT05110040 ·Status: RECRUITING ·Phase: NA
-
Immunological Follow-up of Patients With Basedow's Orbitopathy
NCT04610723 ·Status: COMPLETED
-
Orbital Radiotherapy in Grave's Ophthalmopathy 1 Week vs 2 Weeks (OraGO-1 Trial)
NCT06392906 ·Status: RECRUITING ·Phase: PHASE3
-
Multi-model Image of Doxycycline in TAO
NCT05112211 ·Status: RECRUITING ·Phase: NA
-
Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease
NCT07547930 ·Status: RECRUITING ·Phase: PHASE2
-
Role of the Microbiome in Graves' Orbitopathy
NCT02373995 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Color Doppler Imaging of Orbital Venous Flow in Grave's Orbitopathy
NCT00697528 ·Status: COMPLETED
-
Observing the Relationship of Fibroblast Growth Factor and Fibroblast in Thyroid Eye Disease
NCT03324022 ·Status: UNKNOWN
-
Evaluation of the Corneal Endothelial Cell Layer by Specular Microscopy in Patients With Thyroid Eye Disease
NCT06235372 ·Status: NOT_YET_RECRUITING
-
Changes in Orbital Macrovascular and Intraocular Microvascular Blood Flow After Orbital Decompression Surgery in Patients With Thyroid Eye Disease
NCT07393230 ·Status: COMPLETED ·Phase: NA
-
Using A Novel Classification System in Intravenous GCs Therapy of TAO: A Multi-central, Randomized, Open, Superior Trial
NCT03107078 ·Status: UNKNOWN ·Phase: PHASE4
-
Thyroid-Associated Ophthalmopathy Subtypes and Orbital Antibodies
NCT00430547 ·Status: COMPLETED ·Phase: NA
-
Customized Multiple Orbital Wall Decompression for Sight-threatening Graves's Ophthalmopathy
NCT05627401 ·Status: UNKNOWN
-
Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study
NCT03298867 ·Status: COMPLETED ·Phase: PHASE3
-
AS-OCT of the Cornea in Thyroid Diseases
NCT05241626 ·Status: UNKNOWN
-
Systemic Inflammation, Thyroid Autoimmunity and Neuroretinal Changes in Graves Disease
NCT07480720 ·Status: RECRUITING
-
A Clinical Study of Cizutamig in Thyroid Eye Disease
NCT07597200 ·Status: RECRUITING ·Phase: PHASE1
-
Development of a Non-Invasive Prognostic Test for Graves Orbitopathy
NCT07472062 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
A Study on the Combined Use of Tocilizumab and Flupentixol-Melitracen in the Treatment of Thyroid-Associated Ophthalmopathy
NCT06927375 ·Status: RECRUITING ·Phase: PHASE4
-
Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study
NCT03461211 ·Status: COMPLETED ·Phase: PHASE3
-
Multi-center Prospective Clinical Study on Glucocorticoid Pulse Therapy for Graves' Ophthalmopathy (GO)
NCT06693856 ·Status: ENROLLING_BY_INVITATION ·Phase: NA
-
Disappearance of Graves' Orbitopathy
NCT03103607 ·Status: COMPLETED